What clinical trials have tested Memo Genesis and what were their sample sizes and outcomes?
Executive summary
There are no publicly documented human clinical trials specifically testing the consumer supplement "Memo Genesis" in the supplied sources; investigative and consumer‑advisory pieces state the product’s website and ads lack clear, product‑specific clinical trial data [1] [2]. Separately, a distinct product named "Memo®" (from Pharco Pharmaceuticals) was tested in a randomized, double‑blind, placebo‑controlled pilot trial of 66 patients with mild cognitive impairment over 4 weeks and reported effects on MMSE scores [3].
1. No trace of Memo Genesis clinical trials in available reporting
Multiple consumer‑protection and debunking articles note Memo Genesis is promoted with clinical‑sounding language and celebrity‑style endorsements, but those pieces say the company’s marketing lacks transparent, product‑specific human clinical trial evidence and that public fact‑checks found no verified clinical trials for Memo Genesis itself [1] [2]. Available sources do not mention any peer‑reviewed trial registration or published clinical readouts for "Memo Genesis" as named.
2. Watch the similarly named products — Memo® is a real trial, but it’s a different product
A peer‑reviewed pilot study exists for "Memo®," a dietary supplement from Pharco Pharmaceuticals combining royal jelly, Ginkgo biloba and Panax ginseng; that study randomized 66 subjects with DSM‑IV‑TR defined mild cognitive impairment into Memo® versus placebo for four weeks and measured Mini‑Mental State Examination (MMSE) outcomes [3]. Do not conflate the marketed "Memo Genesis" with this Pharma product: the sources treat them separately and the formulations, sponsors and study contexts differ [3] [1].
3. What the Memo® pilot trial actually tested and its size
The Memo® trial was a randomized, double‑blind, placebo‑controlled pilot conducted in two clinics in Alexandria, Egypt, enrolling 66 participants with clinical mild cognitive impairment; subjects took one Memo® capsule daily for four weeks and investigators evaluated MMSE scores as the primary outcome [3]. That is the only direct clinical trial among the supplied materials that uses the name "Memo" in a controlled human study [3].
4. Outcomes reported for Memo® and limits of generalizing those results
The publication frames the Memo® study as an early pilot suggesting potential MMSE score benefits versus placebo, citing prior rationales (royal jelly, ginkgo, ginseng) for cognitive support and noting this may be the earliest clinical look at that specific triple combination [3]. However, the study was small (n=66), short duration (4 weeks) and targeted mild cognitive impairment; such pilot results require larger, longer, and independently replicated trials before robust clinical claims can be made [3]. The sources do not provide detailed effect sizes or long‑term outcomes in the snippets supplied; for full numerical outcomes consult the PMC article directly [3].
5. Industry activity around "Memo" in biotech is distinct and better documented
"Memo Therapeutics" (Memo Therapeutics AG), an unrelated biotech, has multiple clinical trials for monoclonal antibodies (potravitug/AntiBKV) in kidney transplant infections; these trials are documented with enrollment numbers (e.g., a Phase II potravitug trial enrolled ~90–95 patients across US sites) and corporate press releases [4] [5] [6]. These Memo Therapeutics studies are therapeutics for BK polyomavirus in transplant patients and have nothing to do with cognitive supplements marketed as Memo Genesis [4] [5].
6. Competing viewpoints and possible hidden agendas in the reporting
Consumer sites and malware/advice pages emphasize a scam narrative for Memo Genesis and warn of fake endorsements and lack of trials [1] [2]. Press releases and promotional pieces about MemoGenesis‑style products highlight "evidence‑based" ingredient rationales and market alignment but do not cite independent human trials for that branded product [7]. The promotional material [7] has a commercial tone and may be intended to reassure buyers; fact‑checking and consumer‑advice pieces stress regulatory and evidentiary gaps [1] [2].
7. What’s missing and what to demand from manufacturers
Current reporting does not show clinical trial registration, published randomized trials, sample sizes, or outcome data specifically for Memo Genesis; sources explicitly note that the product’s site lacks clear clinical trial data [1]. Consumers and clinicians should ask manufacturers for trial registrations, protocols, prespecified endpoints, sample sizes, and peer‑reviewed publications before accepting clinical claims—requests supported by the consumer‑advice pieces [1] [2].
8. Bottom line for readers
If you are seeking evidence that "Memo Genesis" has been clinically tested in humans, available reporting and fact‑checks say no such trials are publicly documented [1] [2]. A different product called Memo® does have a small randomized trial (n=66) in mild cognitive impairment with MMSE outcomes [3]; separate biotech firm Memo Therapeutics has clinical trials for unrelated monoclonal antibodies with clearer enrollment figures [4] [5].